GT-02287

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GT-02287 in Parkinson's Disease

Ensayo de Gain Therapeutics, Inc. en Enfermedad de Parkinson.

Más ensayos de: Enfermedad de Parkinson.

Fase: Fase 1
Estado: Reclutando pacientes
Participantes: 20
Centros: 7
Fin del objetivo primario: nov 2025

Qué significa cada fase y cada estado.

Estudio de intervención, de un solo grupo, abierto. Comenzó en feb 2025.

Qué mide

Incidence, nature, relationship to investigational product (IP), and severity of adverse events (AEs) (From first dose to Day 105) (del registro, en inglés)

Qué se prueba

El ensayo evalua la seguridad y tolerabilidad de GT-02287 en personas con enfermedad de Parkinson, administrado una vez al dia durante 90 dias.

Lo que dice el documentoreceive GT-02287 once a day every day for 90 days (90-day Open Label Treatment period) * visit the clinic the first day of treatment, after the first 2 weeks of treatment, and every month during the 90-day Treatment Period. * visit the clinic to assess how they are doing 14 days after the end of GT-02287 treatment (14-day Follow-Up Period).

Traducción automática (claude-sonnet-5). Lo comprobado es la cita: está literal en el documento y sus cifras cuadran con las de la frase. Todavía no la ha leído una persona.

Cómo lo describe el promotor

En el documentoEn inglés, del registroThe main goal of this clinical trial is to learn about the safety and tolerability of GT-02287. The questions it aims to answer are: * What medical problems do participants have when taking GT-02287? * How is GT-02287 absorbed, distributed, and removed from the body of participants over time (pharmacokinetics)? * Are there any biological effects of GT-02287 in blood and in cerebrospinal fluid that could be beneficial for people with Parkinson's disease? Participants will: * visit the clinic to assess if they qualify for the study (30-day Screening Period) * if eligible, receive GT-02287 once a day every day for 90 days (90-day Open Label Treatment period) * visit the clinic the first day of treatment, after the first 2 weeks of treatment, and every month during the 90-day Treatment Period. * visit the clinic to assess how they are doing 14 days after the end of GT-02287 treatment (14-day Follow-Up Period).

Más ensayos de GANX

Ensayo	Fase	Estado	Lectura de resultados
Low Dose GT-02287	Fase 2	Aún sin reclutar	jun 2028 (prevista)

Todos los de GANX, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT06732180), actualizada en may 2025.